Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 29

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 29
---
 or patent applications of our licensors that we have licensed and as confidential know-how
and trade secrets. If the intellectual property that we rely on is not adequately protected, competitors may be able to use our technologies
and erode or negate any competitive advantage we may have.

The patentability of inventions
and the validity, enforceability and scope of patents in the biotechnology field is uncertain because it involves complex legal, scientific
and factual considerations, and it has in recent years been the subject of significant litigation. Moreover, the standards applied by
the U.S. Patent and Trademark Office, or USPTO, and non-U.S. patent offices in granting patents are not always applied uniformly or predictably.
For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology
patents.

35

There is no assurance that all
potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the instances where
searching was done. We may be unaware of prior art that could be used to invalidate an issued patent or prevent a pending patent application
from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability
of a claim of one of our patents or patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability
of such claim. We also may not be able to obtain full patent protection from provisional patents for which we have sought or will seek
further patent protection. As a consequence of these and other factors, our patent applications may fail to result in issued patents with
claims that cover our product candidates in the U.S. or in other countries.

Even if patents have issued or
do successfully issue from patent applications, and even if these patents cover our product candidates, third parties may challenge the
validity, enforceability or scope thereof, which may result in these patents being narrowed, invalidated or held to be unenforceable.
No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable.

Even if unchallenged, our patents
and patent applications or other intellectual property rights may not adequately protect our intellectual property, provide exclusivity
for our product candidates or prevent others from designing around our claims. The possibility exists that others will develop products
on an independent basis which have the same effect as our product candidates and which do not infr